Takeda Chemical Industries, Inc.

Takeda Pharmaceutical Company Limited

Naoru Hamaguchi

Yasuaki Ogawa

Katsumi Iga

Hiroyoshi Koyama

Masahiko Koike

Kazuhiro Doken

Shuji Morimoto

Takatsuka Yashiki

Yoshinobu Yoshimura

Jun Sato

Nobuyoshi Tanaka

Tetsuya Kawano

Nobuyuki Takechi

Akihiro Nagai

Kazuhiro Ohkouchi

Shigehiro Higuchi

Motoya Ohshika

The present invention provides a solid preparation containing an insulin sensitizer and an active ingredient (except insulin sensitizers), which is useful as a therapeutic drug for diabetes and the like, and which is superior in preparation characteristics such as content uniformity and dissolution property of the insulin sensitizer and the active ingredient (except insulin sensitizers), preparation hardness and the like.

Solid preparation

The present invention provides a solid preparation containing an insulin sensitizer and an active ingredient (except insulin sensitizers), which shows in vivo dissolution behavior of an insulin sensitizer, which is similar to the dissolution behavior of an insulin sensitizer from 'a solid preparation containing an insulin sensitizer alone as an active ingredient'. The present invention provides a solid preparation containing (1) a layer containing an insulin sensitizer, and (2) a layer containing (a) an active ingredient (except insulin sensitizers), (b) microcrystalline cellulose having a mean particle size of 5-25 &#x3bc;m, (c) microcrystalline cellulose having a mean particle size of 30-100 &#x3bc;m and (d) polyvinylpyrrolidone K-90.

Solid pharmaceutical preparation

The present invention provides a production method of a preparation coated with pioglitazone hydrochloride, which is useful as a therapeutic agent for diabetes and the like, and which is superior in the characteristics of the preparation such as dissolution property of pioglitazone hydrochloride.

Process for producing coated preparation

A solid preparation useful as a diabetes-treating agent or the like and excellent in the dissolution properties of an insulin sensitizer and an insulin secretagogue, which comprises an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester is provided.

Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester

An object ( ) to be packed is sandwiched between sheet-like package materials ( ). A weakly-sealed portion ( ) is formed so as to surround the packed object ( ) while leaving a grip flap ( ) for each of the package materials ( ), thereby forming a bag portion ( ) which accommodates the packed object ( ) within the weakly-sealed portion ( ). The grip flap ( ) has a length (L) set to about 20 mm for easy handling. The weakly-sealed portion ( ) can be peeled by grasping and pulling the grip flap ( ) to take out the packed object ( ) within the bag portion ( ).

Peelable package and peelable packaging method

A freeze-dried preparation comprising a bioactive substance having an optionally substituted amidino group and a disaccharide which stabilizes the bioactive substance; and a process for making the preparation are described.

Freeze-dried preparation for pharmaceutical use

Disclosed is a sugar-modified cytokine which ensures migration of almost all of the dose of cytokine to the liver rapidly after administration to the live body and which can be advantageously used to enhance the effect of liver disease therapy and mitigate side effects.

Glycosylated cytokines

This invention comprises a pharmaceutical composition comprising a benzimidazole compound having antiulcer activity and a water-soluble carboxylic acid amide. According to this invention, a water-insoluble benzimidazole compound having antiulcer activity can be solubilized and a stable pharmaceutical composition can be provided. The solid pharmaceutical composition of this invention can be extemporaneously dissolved in sterile distilled water or an infusion (e.g. physiological saline, glucose infusion, etc.) and put to use as an injection with great convenience.

Pharmaceutical composition

The liposome compositions entrapping a drug are prepared by constituting the liposomal membrane with a saturated phospholipid and a glycolipid having sulfo group. Thus obtained compositions circulate stably in blood for a long time after intravenous administration.

Liposome composition and its production

The liposome compositions entrapping a drug are prepared by constituting the liposomal membrane with saturated phospholipids and anionic surfactants of high Krafft point at concentrations above their critical micelle concentrations. Thus obtained compositions circulate stably in blood for a long time after intravenous administration.

The liposome compositions entrapping a drug are prepared by constituting the liposomal membrane with a saturated phospholipid and a glycolipid having sialic acid group. Thus obtained compositions circulate stably in blood for a long time after intravenous administration.

Liposome composition and production thereof

Liposomes with an increased drug trap can be prepared by adding a readily volatile organic solvent to a drug-containing liquid with liposomes dispersed therein to cause gel formation and then removing said organic solvent by evaporation.

Method of producing liposome

Liposome compositions in which a drug is retained in stable condition are prepared by dispersing liposomes obtained by removal of a solvent from a drug-containing w/o emulsion in an aqueous solution having an osmotic pressure higher by at least 20 percent than the osmotic pressure of a solution used for entrapping the drug in said liposomes. This composition is conducive to a sustained therapeutic efficacy or a better delivery of the drug to a target organ.

Liposome composition

Cephalosporin derivatives of the formula: ##STR1## wherein R.sub.1 is methyl or ethyl and R.sub.2 is a straight-chain or branched alkyl group of 5 to 7 carbon atoms, and their pharmaceutically acceptable salts, which are effective as orally administrable antibiotic agents against both gram-positive- and negative-bacteria, and the production and compositions thereof, are proposed.

Growing community of inventors

Osaka, Japan

Naoru Hamaguchi